Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity.

Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS.

Nat Med. 2010 Feb;16(2):224-7. doi: 10.1038/nm.2078. Epub 2010 Jan 17.

2.

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.

Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G.

J Gen Virol. 2006 Oct;87(Pt 10):2917-21.

PMID:
16963750
3.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
4.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B.

Virology. 2007 Sep 15;366(1):84-97. Epub 2007 May 11.

5.

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.

6.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

8.

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.

Belyakov IM, Moss B, Strober W, Berzofsky JA.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7.

9.
10.

Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.

Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH.

Vaccine. 2013 Sep 6;31(39):4231-4. doi: 10.1016/j.vaccine.2013.03.017. Epub 2013 Mar 21. Review.

PMID:
23523404
11.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

12.

OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.

Goulding J, Tahiliani V, Salek-Ardakani S.

Immunol Rev. 2011 Nov;244(1):149-68. doi: 10.1111/j.1600-065X.2011.01062.x. Review.

13.

Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.

Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann KM, Lehmann MH, Kalinke U, Sutter G.

PLoS Pathog. 2012;8(3):e1002557. doi: 10.1371/journal.ppat.1002557. Epub 2012 Mar 1.

14.
15.

Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Knitlova J, Hajkova V, Voska L, Elsterova J, Obrova B, Melkova Z.

PLoS One. 2014 Dec 8;9(12):e114374. doi: 10.1371/journal.pone.0114374. eCollection 2014.

16.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

17.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.

18.

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22. Epub 2002 Dec 23.

19.

Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.

Tan X, Sande JL, Pufnock JS, Blattman JN, Greenberg PD.

J Virol. 2011 Aug;85(16):8316-27. doi: 10.1128/JVI.00781-11. Epub 2011 Jun 8.

20.

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.

Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD.

Virology. 2011 Oct 25;419(2):97-106. doi: 10.1016/j.virol.2011.08.005. Epub 2011 Aug 31.

Supplemental Content

Support Center